An indolent subtype of non-Hodgkin lymphoma, follicular lymphoma is characterized by eventual relapse of disease and the need for multiple lines of therapy, adding to the significant disease burden experienced by patients. Novel targeted agents in the relapsed/refractory setting have afforded new treatment options, but important clinical challenges exist, including optimal treatment sequencing, therapy evaluation and patient selection, transitions of care requirements, as well as toxicity management.
In this 1-hour, online activity, lymphoma expert Jeremy Abramson, MD, shares his experience navigating these challenges as part of an interprofessional, multidisciplinary care team.
This activity is also available as a podcast: You may listen here
1 AAPA Category I Hour
1 ACPE Contact Hour
1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
1 CA-BRN Contact Hour
1 Pharmacology Hour
This activity is developed to support hematologist-oncologists, hematology-oncology advanced practice providers, pathologists, and pharmacists who manage patients with follicular lymphoma.
This activity is supported by independent educational grants from Genentech, a member of the Roche Group, and Novartis Pharmaceuticals.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1 hour . Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 contact hour, including 1 pharmacology hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Additional Content PlannersChris Elder, PharmD, BCOP (Medical Writer)
Advisory Board: Eisai, Genentech, Mirati, Novartis, Pfizer, Pharmacosmos, Sanofi
Kimberly Tyler, ANP-C, AOCNP (Nurse Reviewer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
Jeremy S. Abramson, MD, MMSc
Director, Lymphoma Program
Jon and Jo Ann Hagler Chair in Lymphoma
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
- Describe disease burden and unmet clinical needs experienced by patients with follicular lymphoma
- Review current treatment landscape and updates for newly diagnosed and relapsed/refractory follicular lymphoma
- Incorporate recent efficacy and safety data for newly approved and emerging therapies for relapsed/refractory follicular lymphoma into treatment planning
- Develop interprofessional management strategies surrounding complications associated with novel agents including monitoring, toxicity management, and transitions of care
Jeremy S. Abramson, MD, MMSc
Consultant: AbbVie, Astra-Zeneca, BMS, BeiGene, Epizyme, Genentech, Genmab, Interius, Janssen, Kite Pharma, Lilly, Takeda
Research Support: BMS, Cellectis, Merck, Mustang Bio, Seagen